In this episode of DermwireTV, Johnson & Johnson makes a major acquisition to expand its dermatology treatment pipeline; the first high-concentration, citrate-free biosimilar to Humira is launched in the US; and in the C-Suite Chats feature, the CEO of Benev discusses the medical aesthetic market.
ReachMD
Be part of the knowledge.™DermwireTV: J&J Boosts Dermatology Pipeline; New Humira Biosimilar Launched
Choose a format
Media formats available:
Facebook Comments